Mechanistic description
Chronic glial NF-κB activation drives cytokine-mediated dopaminergic toxicity. IKKβ inhibition theoretically reduces neuroinflammation but faces severe safety liabilities (immunosuppression, malignancy risk) and complete absence of human validation, compounded by failed NF-κB-targeting trials in ALS/MS.
Mechanism / pathway
- IKKβ (CHUK)
- neurodegeneration
Evidence for (2)
NF-κB activation observed in PD postmortem tissue
Microglial IKKβ knockout shows neuroprotection in MPTP models (lab-dependent)
Evidence against (3)
Neuronal NF-κB activation is neuroprotective post-MPTP
JAK inhibitors failed in MS; BET inhibitors failed in ALS
Systemic IKKβ inhibition causes pleiotropic effects beyond anti-inflammation
Evidence matrix
Supporting
- NF-κB activation observed in PD postmortem tissue PMID:12181520
- Microglial IKKβ knockout shows neuroprotection in MPTP models (lab-dependent) PMID:19335419
Contradicting
- Neuronal NF-κB activation is neuroprotective post-MPTP PMID:15634647
- JAK inhibitors failed in MS; BET inhibitors failed in ALS PMID:multiple-negative-trials
- Systemic IKKβ inhibition causes pleiotropic effects beyond anti-inflammation PMID:19103757
Cite this hypothesis
Cite this hypothesis
envelope-repair (2026). Microglial IKKβ Inhibition to Block NF-κB-Mediated Inflammation. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-65b13bc5c9
@misc{scidex_hypothesis_h65b13bc,
title = {Microglial IKKβ Inhibition to Block NF-κB-Mediated Inflammation},
author = {envelope-repair},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-65b13bc5c9},
note = {SciDEX artifact hypothesis:h-65b13bc5c9}
}